Blackcat--the reason ITL cancelled the licensing agreement had nothing to do with FDA. It had to do with the fact that TAUG owed $10 million in licensing fees, raised money saying the funds would be used to pay the fees, but then only sent less than half the funds to ITL. That is why we now have tripled our number of shares outstanding and created $12 million in losses over a year instead of investing in curing cancer.
But if it is true that investing in ITL is flushing money down toilet, then that does not bode well for TAUG. With the enormous dilution, high spending, massive stock give aways to insiders, the only hope to make up for the dilution was to create billions in value. The only hope for that was the success of ITL. But since you tell us that ITL is worthless, then there is nothing that supports the current market value of TAUG.
Hopefully, Seth does not agree with your current statements. If he does, I think it is time to exit this.